If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
185
results.
Updated on
16/02/2026 [07:22:00]
Results 175 to 185 of 185
Absstract of: US2025249050A1
The invention relates to core components from five strains of independently isolated, identified and patent-deposited probiotics and fermentation metabolites thereof (postbiotics), as well as their use as a protector in alleviating dextran sulfate sodium (DSS) induced-colitis in mice. Further disclosed the mechanism of the probiotics and fermentation metabolites thereof (postbiotics) to alleviate colitis in mice.
Absstract of: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: WO2025163643A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Absstract of: CN120392795A
The invention discloses application of a natural small molecule K252d in preparation of a medicine for treating inflammatory bowel disease and a preparation method of the medicine, and belongs to the field of biological medicine. K252d can remarkably promote mutual combination of MDM2-FOXP3, improve expression of FOXP3, promote differentiation of iTreg and enhance stability of FOXP3 and a Treg cell inhibition function, so that the effect of treating the inflammatory bowel disease is achieved. Compared with other treatment schemes in the prior art, the target enhancement path provided by the invention has the advantages that the off-target effect is remarkably reduced, and the toxic and side effects are reduced.
Absstract of: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Absstract of: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Absstract of: US2025243546A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Absstract of: WO2025160484A1
Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Absstract of: US2025244312A1
Some embodiments described herein relate to a method of screening candidate therapeutics for gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease, using an ex vivo biopsy high throughput platform. Some embodiments relate to a high-throughput method of screening an ex vivo biopsy for chromatin modifications associated with an gastrointestinal disease. Some embodiments relate to a multi-omic method of screening candidate therapeutics for treatment of gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease.
Nº publicación: US2025244340A1 31/07/2025
Applicant:
MAGNOSTICS LTD [IE]
MAGNOSTICS LIMITED
Absstract of: US2025244340A1
The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).
BOPI
Electronic site
